#AUA2024 great turnout for the MD Anderson Department of Urology alumni gathering at the Fairmont rooftop bar. #oncsurgery Brian F. Chapin

📬 Finally out in The Lancet Oncology the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in National Comprehensive Cancer Network (NCCN) guidelines. Congrats Ashish M. Kamat, MD, MBBS Petros Grivas & team! sciencedirect.com/science/articl…

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…

The gene therapy nadofaragene firadenovec led to durable antitumor activity in a subset of patients with BCG-unresponsive NMIBC. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…

Had a wonderful time at AUA San Antonio, especially catching up with amazing mentors and friends! #AUA2024

🔍 In our latest video, Vikram M. Narayan, MD of Emory University, highlights research presented at #AUA24 on urinary #MRD detection for predicting recurrence and response to #nadofaragene #firadenovec in #BCG -unresponsive #NMIBC .

📚 Read More: buff.ly/3y5Ohd9

Efficacy of nadofaragene firadenovec-vncg for patients with BCG-unresponsive #NMIBC : Final results from a phase 3 trial. Presentation by Vikram M. Narayan, MD Emory Urology. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/4aeth10 Amer. Urol. Assn.

PATHWAY TO PUBLICATION: Efficacy of Intravesical Nadofaragene firadenovec for Patients With BCG-Unresponsive Non–Muscle Invasive Bladder Cancer: 5 Year Follow-up from a Phase 3 Trial. Full article now available... click below #AUA24

bit.ly/44uy0KI

#AUA24 Sima Porten IBCG

Bladder Preserving Options currently available (BCG unresponsive)

UroToday.com

Congratulations to Talia Helman representing Emory Urology with fantastic double hitter BPH presentations on surgical therapy and new technology Brendan Browne

Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC Vikram M. Narayan, MD Winship Cancer Institute of Emory University Emory Urology Amer. Urol. Assn. #AUA24 #AUA2024 #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…

#AUA24 Vikram M. Narayan, MD presented the final results of the phase 3 trial evaluating Nadofaragene firadenovec-vncg versus BCG for BCG-unresponsive NMIBC:

🚩2 Cohorts: CIS±Ta/T1 (CIS; n=107) and Ta/T1 without CIS (papillary disease [PD], (n=50)
🚩HG-RFS rate at 60 months was 5.8%

“At 60 months, nadofaragene allowed bladder preservation in nearly half of the patients in the CIS cohort and two-thirds of patients in the Ta/T1 cohort,” said Vikram Narayan, MD. #AUA24 #bladdercancer Vikram M. Narayan, MD
urologytimes.com/view/nadofarag…

Five-year data from a trial confirms gene therapy nadofaragene firadenovec remains effective against aggressive bladder cancer. #AUA24 #AUA2024 #BLCSM | Vikram M. Narayan, MD Emory Urology Winship Cancer Institute of Emory University

targetedonc.com/view/5-year-da…

#AUA24 Podium presentation Efficacy of Nadofaragene Firadenovec for Patients BCG Unresponsive NMIBC Final Results
Vikram M. Narayan, MD Stephen Boorjian, MD @Colin Dinney@study investigators
At 60M nadofaragene allowed bladder preservation in half of patients in CIS & two-thirds in Ta/T1 cohorts

Excited to present this work at #AUA24 and UTMBUrology being a lead center to provide the data, collaboration, and deploy Valar Labs early access to determine the value stream to our patients. 🎉🙏UTMBPresident UTMB Provost's Office UTMB Health IBCN IBCG Amer. Urol. Assn.